PPARα Agonist Oral Therapy in Diabetic Retinopathy
Diabetic retinopathy (DR) is an eye condition that develops after chronically poorly-managed diabetes, and is presently the main cause for blindness on a global scale. Current treatments for DR such as laser photocoagulation, topical injection of corticosteroids, intravitreal injection of anti-vascu...
Main Authors: | Yohei Tomita, Deokho Lee, Kazuo Tsubota, Toshihide Kurihara |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/8/10/433 |
Similar Items
-
The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
by: Treacy Maxwell P, et al.
Published: (2012-09-01) -
Effect of RAGE -429T / C and Gly82Ser Gene Polymorphism in Diabetic Retinopathy in General Hospital Mohammad Hoesin Palembang
by: Riani Erna, et al.
Published: (2017-10-01) -
Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy
by: Yohei Tomita, et al.
Published: (2020-08-01) -
Sulforaphane Inhibits MGO-AGE-Mediated Neuroinflammation by Suppressing NF-κB, MAPK, and AGE–RAGE Signaling Pathways in Microglial Cells
by: Lalita Subedi, et al.
Published: (2020-08-01) -
Role of advanced glycation end products and sorbitol dehydrogenase in the pathogenesis of diabetic retinopathy
by: Leqaa A. Moemen, et al.
Published: (2020-04-01)